Entering text into the input field will update the search result below

Proof of Olysio + Sovaldi?

Apr. 15, 2014 3:51 PM ETJohnson & Johnson (JNJ) StockGILD, JNJBy: Douglas W. House, SA News Editor8 Comments
  • Johnson & Johnson's (JNJ +2%) hepatitis C drug Olysio (simeprevir) blew out Q1 expectations with its $354M in sales. Wells Fargo analyst Lawrence Biegelsen forecasted only $23M.
  • Some observers believe that many physicians are prescribing the drug in combination with Gilead's (GILD +2.3%) Sovaldi (sofosbuvir) thereby inflating the full regimen cost to ~$150,000 in the U.S.
  • A 12-week course of treatment of Olysio costs $66,360.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson